Cost-Effectiveness of Adjuvant FOLFOX Therapy for Stage III Colon Cancer in Japan Based on the MOSAIC Trial

2009 Cunningham, 2010, Colorectal cancer, Lancet, 375, 1030, 10.1016/S0140-6736(10)60353-4 1995, Efficacy of adjuvant fluorouracil and folinic acid in colon cancer, Lancet, 345, 939, 10.1016/S0140-6736(95)90696-7 Wolmark, 1993, The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03, J Clin Oncol, 11, 1879, 10.1200/JCO.1993.11.10.1879 Wolmark, 1999, J Clin Oncol, 17, 3553, 10.1200/JCO.1999.17.11.3553 de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938 Andre, 2004, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 350, 2343, 10.1056/NEJMoa032709 Kuebler, 2007, Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07, J Clin Oncol, 25, 2198, 10.1200/JCO.2006.08.2974 Andre, 2009, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J Clin Oncol, 27, 3109, 10.1200/JCO.2008.20.6771 Eggington, 2006, Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer, Br J Cancer, 95, 1195, 10.1038/sj.bjc.6603348 Aballea, 2007, Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US, Cancer, 109, 1082, 10.1002/cncr.22512 Attard, 2010, Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada, Curr Oncol, 17, 17, 10.3747/co.v17i1.436 Weinstein, 1996, Recommendations of the Panel on Cost-effectiveness in Health and Medicine, JAMA, 276, 1253, 10.1001/jama.1996.03540150055031 Shiroiwa, 2009, Health utility scores of colorectal cancer based on societal preference in Japan, Qual Life Res, 18, 1095, 10.1007/s11136-009-9513-z 2010 2010 Lin, 1997, Estimating medical costs from incomplete follow-up data, Biometrics, 53, 419, 10.2307/2533947 Boag, 1949, Maximum likelihood estimates of the proportion of patients cured by cancer therapy, J RStat Soc B, 11, 15 2008 Shiroiwa, 2010, International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?, Health Econ, 19, 422, 10.1002/hec.1481 2006